(Reuters) – German packaging and medical equipment maker Gerresheimer is contracted to supply key players in the market for GLP-1 weight loss drugs, its CEO Dietmar Siemssen said on Thursday.
“We are serving all key players in the GLP-1 market,” he said during an earnings call. “There are only two key players there.”
The current sales result is thanks to deliveries to these customers, he added.
GLP-1 is a type of obesity drug such as Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound, which is administered by injector pens such as those made by Gerresheimer.
(Reporting by Isabel Demetz, editing by Andrey Sychev)
